Strengthen cooperation in the pharmaceutical bio industry between Korea and Japan...Korea Pharmaceutical Bio Association, Ministry of Food and Drug Safety Dispatch Joint Public-Private Delegation to Japan
Jul 17, 2025
|
According to the Korea Pharmaceutical and Biotechnology Association, the joint delegation visit is aimed at expanding exchanges and laying the foundation for cooperation with Japan, the world's third largest pharmaceutical market, and will be held for three days from July 16-18, focusing on Tokyo and Kanagawa.
The delegation consisted of a total of 31 experts, including industry and government officials, Kim Kook-hee, head of the Health Insurance Review and Assessment Service, and Ahn Jung-hoon, a professor at Ewha Womans University's New Industrial Convergence University, led by Lee Jae-guk, vice chairman of the Korea Pharmaceutical and Bio Association, and Kim Sang-bong, director of drug policy at the Ministry of Food and Drug Safety.
The delegation will hold a visit to the Japan Pharmaceutical Association (JPMA, Chairman Kenji Kinoshita) of the Korea Pharmaceutical and Biotechnology Association on the 16th, the first day of their visit to Japan, and a local meeting between the Ministry of Food and Drug Safety and industry representatives, followed by the 6th Korea-Japan joint symposium and networking reception on the 17th. On the 18th, he will visit Japan's largest biocluster, Shonan iPark', examine the local bio venture ecosystem and corporate support infrastructure, and explore practical business cooperation such as mutual technology cooperation and joint R&D. Shonan I-Park, which was built in Fujisawa City, Kanagawa Prefecture, near Tokyo in 2018, has a total floor area of 90,000 pyeong, and 192 companies and institutions, including eight Korean bio ventures, are conducting joint research.
During this visit, the Ministry of Food and Drug Safety will hold a director-level bilateral meeting with Japan's Ministry of Health, Labor and Welfare (MHLW) and the General Organization of Pharmaceutical and Medical Devices (PMDA) to discuss regulatory harmonization and industrial cooperation. In particular, this year marks the 10th anniversary of the signing of a memorandum of understanding (MOU) between Korea and Japan, and plans to seek mutual cooperation with a focus on expanding future-oriented regulatory cooperation between the two countries.
Vice Chairman Lee Jae-guk said, "It is a very meaningful opportunity for the regulators of both Korea and Japan to discuss a sustainable cooperative model at a time when the global pharmaceutical bio industry is facing various challenges. We will continue to provide active support to the public-private partnership forum to further strengthen cooperation between the public and private sectors and to lead to practical business between the two companies."."
This article was translated by Naver AI translator.
